Avidity has Reached Alignments with the FDA on the Ph3 FSHD and DM1 Study Designs. The randomized, double-blind, placebo-controlled confirmatory Phase 3 FORWARD study in FSHD will enroll approximately 200 patients for 18 months of treatment. The study will evaluate the clinical benefit from del-bra
Arcus Biosciences (RCUS) Feb. 28, 2026: Additional ARC-20 data including activity and biomarker analysis of cas in ccRCCAscendis Pharma (ASND) Feb. 28, 2026: PDUFA date for TransCon CNP for pediatric achondroplasiaBioMarin Pharmaceutical (BMRN) Feb. 28, 2026: PDUFA date for Palynziq for adolescent
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.